Ash 2019 – former Celgene holders look anxiously at contingent value
Celgene CVR holders have been desperate to find out whether JCAR017 is approvable. Yesterday at Ash they got their answer... kind of.
Allogene and the need for a reliable cell source
A recent technology deal with Notch points to a problem that all allogeneic cell therapy players might sooner or later have to tackle.
First blood: Rubius approaches its big test
The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…
Reneuron’s reinvention falters
More data with the group’s retinal stem cells have disappointed, but the company brushed off two cases of vision loss.
Vertex spends nearly $1bn on Semma's unproven diabetes cell tech
Having succeeded with cystic fibrosis Vertex is now chasing a cure for type 1 diabetes.
Autolus slams on the brakes in its Car
Blaming manufacturing delays and competitive pressure, Autolus asks investors to reset expectations.
Bluerock unlikely to smooth Bayer’s rocky road
Bayer has responded to its current woes by going all in on cell therapy – a move that, even if successful, will take a long time to pay off.
Upcoming events – Atara and Aslan await validating results
Atara tackles multiple sclerosis’s virus hypothesis while Aslan needs to roar with crucial biliary tract cancer data.
Neon and Neurotrope await signs of proof of concept
Neon Therapeutics is due to unveil the first rigorous test of its neoantigen approach to fighting tumours, while Neurotrope makes a brave bid in Alzheimer's.
